<DOC>
	<DOCNO>NCT02387229</DOCNO>
	<brief_summary>This prospective , multicenter , randomize , double-blinded clinical trial explore efficacy safety rivaroxaban compare acetylsalicylic acid reduce stroke , transient ischemic attack ( TIA ) neurocognitive decline , subject non-valvular AF low risk stroke .</brief_summary>
	<brief_title>Blinded Randomized Trial Anticoagulation Prevent Ischemic Stroke Neurocognitive Impairment AF</brief_title>
	<detailed_description>Subjects qualify approach consent enrolled undergo baseline evaluation include modify mini mental state test ( 3MS ) . Subjects without clinical diagnosis dementia Mini Mental State Examination score ( MMSE ) score ≥ 25 undergo neurocognitive assessment ( MoCA ) , psychosocial QoL assessment randomization . During follow-up period double-blind treatment period ( minimum 3 6.5 year depend length recruitment ) , subject receive study medication fix dos . During follow-up period , subject visit clinic every 6 month maximum 78 month . Subjects take either rivaroxaban 15 mg match acetylsalicylic acid - placebo acetylsalicylic acid 100 mg match rivaroxaban-placebo orally , daily , preferably time day throughout study . An independent clinical event committee classify endpoint event . An independent Data Safety Monitoring Committee ( DSMC ) establish monitor progress study assure safety subject enrol trial .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>For entry study , follow criterion must meet : Age consent ≥30 ≤61 year Nonvalvular atrial fibrillation ( paroxysmal , persistent permanent ) document electrical tracing ( routine 12lead electrocardiogram [ ECG ] , Holter monitor [ continuous ECG record ] rhythm strip , intracardiac electrogram , pacemaker implantable cardiac defibrillator interrogation least 30 ) within prior 18 month Low risk stroke define absence following : . Prior stroke Transient Ischemic Attack , ii . Hypertension , iii . Diabetes mellitus , iv . Congestive heart failure ( New York Heart Association class II high time enrolment know leave ventricular ejection fraction &lt; 35 % ) ; Signed write informed consent For entry study , none follow criterion MUST meet Known diagnosis dementia ; Valvular AF ( Clinically significant ( severe moderate ) rheumatic mitral stenosis , mechanical bioprosthetic heart valve , mitral valve repair ) hypertrophic cardiomyopathy ; Other indication antiplatelet therapy anticoagulation ; History GI bleeding ; Conditions associate increase risk bleed describe follow : 1 . Major surgery within previous month ; 2 . Planned surgery intervention within next 3 month ; 3 . History intracranial , intraocular , spinal , retroperitoneal traumatic intraarticular bleeding ; 4 . Symptomatic endoscopically document gastroduodenal ulcer disease previous 30 day ; 5 . Haemorrhagic disorder bleed diathesis ; 6 . Fibrinolytic agent within 48 hour study entry ; 7 . Recent malignancy radiation therapy ( within 6 month time enrolment ) expect survive 3 year ; Reversible cause AF ( e.g . cardiac surgery , pulmonary embolism , untreated hyperthyroidism ) ; Plan perform pulmonary vein ablation surgery treatment AF ; Absence recurrence AF 3 month AF ablation ; Severe renal impairment ( creatinine clearance 30 mL/min less ) ; Active infective endocarditis ; Active liver disease ( e.g . acute clinical hepatitis , chronic active hepatitis , cirrhosis ) , Alanine Transaminase ( ALT ) &gt; 3 time upper limit normal ; Women pregnant childbearing potential use medically acceptable form contraception throughout study ; Women breastfeeding ; Anemia thrombocytopenia ( accord normal range value local laboratory ) ; Participation another study involve investigational drug ( development ) time within 30 day randomisation ; Subjects consider unreliable , life expectancy le 3 year condition , opinion investigator , would allow safe participation study ( e.g . drug addiction , alcohol abuse ) ; Known diagnosis major depression within past year .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Stroke</keyword>
	<keyword>Neurocognitive decline</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Acetylsalicylic acid</keyword>
	<keyword>Anticoagulation</keyword>
</DOC>